Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# MedWorks Media: The Voice of Science

## Sitemaps
[XML Sitemap](https://medworksmedia.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [GLP-1 medications linked to reduced psychiatric hospital visits](https://medworksmedia.com/glp-1-medications-linked-to-reduced-psychiatric-hospital-visits/): GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows. The large register-based study was carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia.
- [Lipocine Reports Steady Enrollment Progress in Pivotal Phase 3 Trial of Oral Brexanolone (LPCN 1154) for Postpartum Depression](https://medworksmedia.com/lipocine-reports-steady-enrollment-progress-in-pivotal-phase-3-trial-of-oral-brexanolone-lpcn-1154-for-postpartum-depression/): Salt Lake City, UT — Lipocine Inc. announced positive progress in its pivotal phase 3 clinical trial evaluating oral brexanolone (LPCN 1154) for the treatment of postpartum depression (PPD). The study has reached one-third of its planned enrollment, with topline results expected in the second quarter of 2026.
- [Bristol Myers Squibb Gets FDA Fast Track Designation for Investigational Alzheimer’s Agent](https://medworksmedia.com/bristol-myers-squibb-gets-fda-fast-track-designation-for-investigational-alzheimers-agent/): Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti–microtubule binding region tau (anti–MTBR-tau) antibody currently in phase 2 development for the treatment of early Alzheimer disease (AD).
- [Beyond Dopamine: Emerging Mechanisms Reshaping Psychopharmacology](https://medworksmedia.com/beyond-dopamine-emerging-mechanisms-reshaping-psychopharmacology/): What if the next leap in psychiatric treatment doesn’t come from tweaking dopamine or serotonin, but from reengineering the immune system, harnessing neuroplasticity, or refining orexin antagonism? In 2025, the psychopharmacology landscape is tilting toward novel, precision-guided targets. Clinicians and R&D teams alike must stay alert—not for incremental tweaks, but for paradigm shifts.
- [2025 in Psychopharmacology: New Mechanisms, Pipeline Pivots & Clinical Implications](https://medworksmedia.com/2025-in-psychopharmacology-new-mechanisms-pipeline-pivots-clinical-implications/): By mid-2025, the psychopharmacology landscape feels paradoxical: on one hand, deeply familiar challenges — slow response, heterogeneity, side effects — still dominate clinical reality. On the other, a wave of novel mechanisms, smarter trial designs, and biomarker-driven strategies promise to reshape how we think about psychiatric drug development. Which trends might finally break through, and which disappointments are forcing course corrections?
- [Psychopharmacology Bulletin: September 2025 Edition](https://medworksmedia.com/psychopharmacology-bulletin-september-2025-edition/): What if the next leap in psychiatric therapeutics comes not from entirely new receptors, but from smarter targeting—or smarter delivery? From LSD-derived anxiety relief to once-weekly schizophrenia pills, this week’s developments hint at a transition zone: between the incremental and the transformational.
- [Precision Psychiatry on the Horizon: Biomarkers, Psychoplastogens, and Predictive EEG](https://medworksmedia.com/precision-psychiatry-on-the-horizon-biomarkers-psychoplastogens-and-predictive-eeg/): Key Updates Biomarker-Stratified Antidepressant ResponseA randomized trial in JAMA Psychiatry (Sept 2025) found that patients with treatment-resistant depression who carried the ANK3 biomarker had improved outcomes with liafensine, suggesting potential for genotype-guided prescribing (doi:10.1001/jamapsychiatry.2025.xxxxx). Global R&D TrendsAn analysis of 1,377 psychiatric drug clinical trials in China (2019–2024) reported a shift toward biomarker-based and exploratory designs, with depression (30.9%) and schizophrenia (22.2%) dominating pipelines. Fifty-two innovative agents are in active testing (Front Psychiatry, 2025; doi:10.3389/fpsyt.2025.1599038). Non-Hallucinogenic PsychoplastogensNovel compounds such as DLX-159 and bretisilocin show preclinical or early-phase efficacy in promoting plasticity without hallucinogenic effects, potentially expanding accessibility beyond tightly regulated psychedelic protocols (Delix/Gilgamesh trial updates, 2025). SIRT6 Modulation in Depression & SchizophreniaForvisirvat (SP-624), a SIRT6 activator, is advancing in Phase II/III depression and Phase I/II schizophrenia trials, representing a mechanistically distinct class targeting epigenetic regulation (pipeline update, 2025). Predictive EEG BiomarkersDay-7 EEG motif analysis demonstrated the ability to classify antidepressant responders vs. non-responders with high accuracy, potentially shortening ineffective trials of therapy (arXiv preprint:2501.04441, 2025). Clinical Takeaways Biomarkers (genomic, EEG) may enable earlier, more precise treatment shifts. Psychoplastogens could reduce barriers to psychedelic-based interventions. Novel mechanistic targets (e.g., SIRT6) suggest a broadening antidepressant landscape. References JAMA Psychiatry. 2025 Sep 10. doi:10.1001/jamapsychiatry.2025.xxxxx Zhang et al. Front Psychiatry. 2025;16:1599038. doi:10.3389/fpsyt.2025.1599038 Delix Therapeutics pipeline. Accessed Sept 2025. Gilgamesh Pharmaceuticals trial registry. Accessed Sept 2025. 2025 Jan. arXiv:2501.04441
- [Rapid-Acting, Novel Modalities & Regulatory Wins: Where Psychopharmacology Stands in Late 2025](https://medworksmedia.com/rapid-acting-novel-modalities-regulatory-wins-where-psychopharmacology-stands-in-late-2025/): From Psychedelics to Mechanism-Driven Precision: Recent Shifts in Depression Treatment
- [US Abortion Restrictions and the Neuropsychiatric Health of Pregnant Individuals and Families](https://medworksmedia.com/us-abortion-restrictions-and-the-neuropsychiatric-health-of-pregnant-individuals-and-families/): Recent changes in the legal landscape in the United States have affected access to abortion, and this restricted access has profound effects on both physical and mental health of reproductive-aged women and their families.
- [FDA Reviews Brexpiprazole-Sertraline Combo for PTSD](https://medworksmedia.com/fda-reviews-brexpiprazole-sertraline-combo-for-ptsd/): The FDA’s Psychopharmacologic Drugs Advisory Committee is evaluating a New Drug Application (NDA) for a combination of brexpiprazole and sertraline as a potential treatment for posttraumatic stress disorder (PTSD). If approved, it would mark the first new PTSD therapy in more than two decades. Current options—mainly selective serotonin reuptake inhibitors (SSRIs) such as sertraline and paroxetine—often provide limited relief.
- [Johnson & Johnson Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse](https://medworksmedia.com/johnson-johnson-submits-snda-to-fda-for-caplyta-to-prevent-schizophrenia-relapse/): Johnson & Johnson recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for lumateperone (Caplyta®), based on long-term data supporting its safety and efficacy in preventing relapse in schizophrenia.
- [Autoimmune Diseases Linked to Increased Risk for Mood Disorders](https://medworksmedia.com/autoimmune-diseases-linked-to-increased-risk-for-mood-disorders/): A study of 1.5 million UK adults found that autoimmune diseases are linked to a nearly twofold increase in the risk for mood disorders such as depression, anxiety, and bipolar disorder compared with the general population. The research, published in BMJ Mental Health, highlights the importance of regular mental health screenings for individuals with autoimmune conditions. The observational study used data from the Our Future Health cohort and included six autoimmune conditions: rheumatoid arthritis, Graves’ syndrome, inflammatory bowel disease, lupus, multiple sclerosis, and psoriasis. Women with autoimmune conditions showed a higher prevalence of mood disorders compared with men. The study suggests that chronic inflammation may contribute to these mental health issues, though further research is needed to explore causal mechanisms. The authors were supported by funding from the UK Medical Research Council.
- [Semaglutide May Lower Dementia Risk in T2 Diabetes](https://medworksmedia.com/semaglutide-may-lower-dementia-risk-in-t2-diabetes/): Semaglutide, a medication for type 2 diabetes (T2D), is associated with a 20%-46% reduced risk for Alzheimer's disease-related dementia compared with other antidiabetic drugs. A study analyzed electronic health records of over 1.7 million US adults with T2D, focusing on dementia diagnoses over three years. Semaglutide showed a stronger protective effect against vascular dementia than insulin, metformin, and older glucagon-like peptide 1 receptor agonists. The risk reduction was more pronounced in younger adults. The study suggests semaglutide's potential in reducing dementia-related medication prescriptions. The study highlights the need for further research to establish causal relationships and understand underlying mechanisms. The study was funded by the National Institute on Aging and the National Center for Advancing Translational Sciences.
- [New Guidelines Aim to Standardize Psychedelic Clinical Trials](https://medworksmedia.com/new-guidelines-aim-to-standardize-psychedelic-clinical-trials/): An international panel of 89 experts from 17 countries has developed new guidelines—Reporting of Setting in Psychedelic Clinical Trials (ReSPCT)—to standardize how psychedelic clinical trials report 'set and setting,' the mindset and environment in which psychedelic experiences occur. Published in Nature Medicine, the guidelines outline 30 variables across four key areas: physical environment, dosing session procedures, therapeutic framework, and participants’ subjective experiences.
- [Weekly Oral Risperidone Pill Shows Promise in Schizophrenia](https://medworksmedia.com/weekly-oral-risperidone-pill-shows-promise-in-schizophrenia/): A Phase 3 clinical trial has shown that LYN-005—a once-weekly oral capsule formulation of risperidone—achieves comparable bioavailability and symptom control to daily dosing in patients with schizophrenia or schizoaffective disorder. Conducted at five sites across the U.S. and enrolling 83 participants, the study was stopped early following positive interim results. Designed to release risperidone gradually in the stomach, LYN-005 may offer a middle ground between daily oral medications and long-acting injectable options, potentially improving patient adherence.
- [Early Psychological Therapy Improves Post-Stroke Depression and Anxiety](https://medworksmedia.com/early-psychological-therapy-improves-post-stroke-depression-and-anxiety/): Psychological therapy has been shown to significantly alleviate depression and anxiety in stroke survivors, particularly when initiated within six months of the stroke event. In a study involving over 7,000 adults in England, 71% experienced a reliable improvement in symptoms, while 49% achieved reliable recovery. Patients who began therapy more than a year after their stroke had 20% lower odds of recovery. Outcomes were assessed using the Patient Health Questionnaire and the Generalized Anxiety Disorder scale, with results indicating moderate to large reductions in symptom severity. These findings highlight the critical importance of timely psychological intervention for stroke patients. The study was funded by the Alzheimer’s Society.
- [Synthetic psilocybin demonstrates a significant reduction in treatment-resistant depression symptoms](https://medworksmedia.com/synthetic-psilocybin-demonstrates-a-significant-reduction-in-treatment-resistant-depression-symptoms/): A Phase 3 clinical trial of COMP360, a synthetic formulation of psilocybin, showed a significant reduction in symptoms of treatment-resistant depression. Conducted at 32 sites across the U.S. with 258 participants, the study found that a single 25 mg dose led to greater symptom improvement on the Montgomery-Åsberg Depression Rating Scale compared to placebo over a six-week period. No unexpected safety concerns or increases in suicidal ideation were reported. This marks the first Phase 3 trial to demonstrate efficacy for a synthetic psilocybin. Compass Pathways, the manufacturer of COMP360, plans to present the findings to the FDA. A second Phase 3 trial, involving 568 participants across North America and Europe, is underway, with results anticipated in 2026. All studies are funded by Compass Pathways.
- [Two New Studies Explore Risk Prediction for Postpartum Mental Health Conditions](https://medworksmedia.com/two-new-studies-explore-risk-prediction-for-postpartum-mental-health-conditions/): Two new studies examining mental health risks postpartum were published online in the American Journal of Psychiatry in conjunction with Maternal Mental Health Awareness Month and the 2025 Annual Meeting of the American Psychiatric Association (APA). One study sought to estimate the risk of postpartum depression in people without a history of depression, and the other looked at the familial contribution to the risk of postpartum psychosis. Researchers from both studies were on hand to discuss their findings at a special briefing held at the APA meeting.
- [Novel Blood Test Could Help Diagnose and Track Alzheimer’s](https://medworksmedia.com/novel-blood-test-could-help-diagnose-track-alzheimers/): A novel blood test that detects a key biomarker for Alzheimer’s disease (AD) could help physicians more accurately determine the presence and track disease progression.
- [New 48-Week Remission Data on Ingrezza for the Treatment of TD](https://medworksmedia.com/new-48-week-remission-data-on-ingrezza-for-the-treatment-of-td/): Neurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once-daily valbenazine (Ingrezza) capsules, at the 2025 Psychiatry Update Conference in Chicago.1  The conference was first reported in Psychiatric Times
- [Efficacy of esketamine for perinatal depression](https://medworksmedia.com/efficacy-of-esketamine-for-perinatal-depression/): Objective
- [A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain](https://medworksmedia.com/a-systematic-review-on-the-efficacy-of-glp-1-receptor-agonists-in-mitigating-psychotropic-drug-related-weight-gain/): Objective
- [Efficacy of vortioxetine versus desvenlafaxine: Results from the multinational VIVRE study](https://medworksmedia.com/efficacy-of-vortioxetine-versus-desvenlafaxine-results-from-the-multinational-vivre-study/): Background
- [General Anesthesia for Cesarean Deliveries Show Link to Postpartum Depression](https://medworksmedia.com/general-anesthesia-for-cesarean-deliveries-a-risk-to-mental-health/): According to a brief on Medscape, supported by the NIH, The use of general anesthesia during cesarean deliveries is associated with an increased risk for postpartum depression (PPD) that necessitates hospitalization as well as a risk for suicidality, regardless of obstetric complications.
- [First Episode Psychosis in a Teen with Narcolepsy and Cataplexy](https://medworksmedia.com/first-episode-psychosis-in-a-teen-with-narcolepsy-and-cataplexy/): Writing in Psychopharmacology Bulletin, Trishna Sharma, Annette C. Kestner and Abhishek Reddy described a 17-year-old female with a history of NT1 and no past psychiatric history presented to the hospital from the community due to a psychotic episode of unknown etiology. During this event, she was told by “the Lord” to cross the street, which consisted of a four-lane highway, with her eyes closed, and she did this five times before returning to her workplace. She was noted to be praying and talking to herself. Before this event, the patient had received high grades and was employed part-time. There was no reported history of substance use. The patient does not have a family history of psychiatric illness and does not have any concerns with meeting her developmental milestones.
- [Complete Resolution of Catatonia Following a Single Intravenous Lorazepam Challenge Test: An Early Intervention in Psychosis Case Report](https://medworksmedia.com/complete-resolution-of-catatonia-following-a-single-intravenous-lorazepam-challenge-test-an-early-intervention-in-psychosis-case-report/): Writing in Psychopharmacology Bulletin, authors Chinenye Okoro, Kaye Homer, Marlene Kelbrick, Jonny Walker, Mary Sam, Justine Burge, Rosie Richards, Gabriela Paduret, and Feras Ali Mustafa examined a 53-year-old Caucasian female who had been under the care of the early intervention for psychosis (EIP) service following a first episode psychosis. At the time of first presentation an incidental finding of a small meningioma was diagnosed through contrast MRI brain scan. The psychotic episode appeared unrelated to this following acute liaison psychiatric and neurology review and was thought to be stress-related at the time. There was no history of substance misuse, other significant medical illness or family psychiatric history. The patient had in recent months reported symptoms suggestive of being in the perimenopausal phase that include changes in menstrual cycle. Although not formally diagnosed, the patient also presented with possible features of autistic spectrum disorder. Following a first episode psychosis, the patient was briefly treated with aripiprazole (antipsychotic) up to a dose of 10 mg in the morning. The patient stopped medication 3 months later. She remained well and stable following medication cessation.
- [Early Positive Report of Viloxazine for a Child with Hyperkinetic Autism](https://medworksmedia.com/early-positive-report-of-viloxazine-for-a-child-with-hyperkinetic-autism/): Ahmed Naguy, Nadyah Alayadhi, Saxby Pridmore, Bibi Alamiri, writing in Psychopharmacology Bulletin, made the following observations:
- [Salty Despair: An Adolescent’s Suicide Attempt through Salt Overdose](https://medworksmedia.com/salty-despair-an-adolescents-suicide-attempt-through-salt-overdose/): Salt is found in nearly every kitchen across the world; however, it is not typically thought of to be a means for suicide. Depending on the age and size of the person, anywhere from 2 to 4 tablespoons of salt consumed rapidly can be lethal. To put that in perspective, the average person in the United States consumes approximately 0.5 tablespoons of salt over the course of the day, which is still above what is recommended. Most cases discussing salt overdose or salt poisoning happen accidentally, however there are case studies and reviews discussing intentional salt overdoses that mostly occur either as exorcism rituals in adults or parents poisoning their young children in cases of factitious disorder imposed on another.
- [Crisis lines testing AI to help review response](https://medworksmedia.com/crisis-lines-testing-ai-to-help-review-response/): Crisis support lines are currently undergoing testing of artificial intelligence (AI) to assess the quality of their response. These support lines rely on well-trained counselors who are adept at handling sensitive conversations, particularly those involving potential suicide. However, the process of reviewing randomly selected recordings to ensure quality control is putting additional strain on these already burdened services. This challenge is further exacerbated by the introduction of the new 988 system, which in May alone directed nearly 470,000 calls to crisis support lines.
- [New APA Study Shows a Spike in Anxiety Among a Large Swath of America](https://medworksmedia.com/new-apa-study-shows-a-spike-in-anxiety-among-a-large-swath-of-america/): According to the American Psychiatric Association's annual poll, 70% of adults in the United States report feeling anxious or extremely anxious about their own and their family's safety. This number is 6% higher than in the past two years, although lower than during the early stages of the pandemic in 2020. The Healthy Minds Monthly series, conducted by the APA in collaboration with Morning Consult, explores anxiety levels regarding current events. In the past month, the percentage of adults who feel very anxious about gun violence has risen by 5 points to 42%.
- [Neuromodulation Device for Depression Granted Designation from FDA](https://medworksmedia.com/neuromodulation-device-for-depression-granted-designation-from-fda/): According to published reports, The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Sooma Medical's portable, noninvasive neuromodulation device for treating depression, which can be administered by the patient. The device, which uses transcranial direct current stimulation to target specific areas of the brain and alleviate depressive symptoms, has a treatment duration of 30 minutes per session, with electrodes that automatically turn off after completion. The treatment regimen involves sessions five days a week for three weeks, after which the clinician can evaluate the patient's progress and decide on further steps. Sooma CEO Tuomas Neuvonen expressed enthusiasm about the designation and the opportunity to make the device accessible to US patients. Clinical studies have shown that after approximately 16 sessions, more than half of participants reported at least a 50% reduction in depressive symptoms, while 19.5% achieved remission. The study's authors noted that this is the most extensive real-world data on the efficacy and tolerability of transcranial direct current stimulation for the treatment of Major Depressive Disorder.
- [Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression](https://medworksmedia.com/comparative-effectiveness-of-intravenous-ketamine-and-intranasal-esketamine-in-clinical-practice-among-patients-with-treatment-refractory-depression/): Objective: To compare the efficacy and speed of achieving remission/response in treatment-resistant depression (TRD) patients treated with subanesthetic intravenous (IV) ketamine and intranasal (IN) esketamine approved by the US Food and Drug Administration (FDA).
- [Pimavanserin Shows Promise for MDD](https://medworksmedia.com/pimavanserin-shows-promise-for-mdd/): In a phase 2 study, pimavanserin showed promise as a treatment for major depressive disorder (MDD) when used in combination with other antidepressants. Two phase 3 studies were then conducted to further evaluate its efficacy and safety in patients with MDD who had not responded well to existing antidepressant treatment. The studies were combined due to challenges in recruitment caused by the COVID-19 pandemic.
- [FDA Approves Second Anti-Amyloid for Alzheimer’s Disease](https://medworksmedia.com/fda-approves-second-anti-amyloid-for-alzheimers-disease/): The US Food and Drug Administration (FDA) has approved the anti-amyloid beta protofibril antibody lecanemab (Leqembi, Eisai) for the treatment of early Alzheimer's disease (AD). The agency approved the treatment on the basis of findings from the CLARITY AD trial, which showed modest cognitive benefit for patients with early AD ― but at a cost of increased risk for amyloid-related edema and effusions.
- [Study finds association between sleep duration and multimorbidity](https://medworksmedia.com/study-finds-association-between-sleep-duration-and-multimorbidity/): In a study published in PLOS Medicine that uses data spanning 25 years, the authors observed short sleep duration to be associated with risk of chronic disease and subsequent multimorbidity but not with progression to death. There was no robust evidence of an increased risk of chronic disease among those with long sleep duration at age 50. Our findings suggest an association between short sleep duration and multimorbidity. Data were drawn from the prospective Whitehall II cohort study, established in 1985 on 10,308 persons employed in the London offices of the British civil service.
- [First of its kind drug, to reverse effects of cocaine intoxication, awarded grant](https://medworksmedia.com/first-of-its-kind-drug-to-reverse-effects-of-cocaine-intoxication-awarded-grant/): An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health.
- [Mechanisms and Necessity of Psychedelic ‘Tripping’](https://medworksmedia.com/mechanisms-and-necessity-of-psychedelic-tripping/): It is known that psychedelics activate serotonin 2A receptors, which eventually leads to states like increased empathy and out-of-body experiences. One of the key questions remaining n psychedelic medicine is quantifying how this class of drugs operates at the higher-order brain level.
- [News Snippet:  School Year and Suicidal Behaviors Among Youth](https://medworksmedia.com/news-snippet-school-year-and-suicidal-behaviors-among-youth/): Suicidal behaviors were higher during the school year (average of 6,761/month) compared to school break (average of 4,512/month). Prevalence of suicidal behaviors was highest in October for both hospitalization and primary diagnosis of mood disorder. Among the school year cohort, the rate of suicidal behaviors was higher in youth with mood disorders (91.6% vs 90%). During school break, the suicidal behavior rate was higher for youth with disruptive behavior disorders (34.6% vs 31.5%) and comorbid alcohol (7.9% vs 5.7%) and other substance use disorders (21.7% vs 18.4%).
- [Best Meds for Insomnia](https://medworksmedia.com/best-meds-for-insomnia/): Two drugs have emerged as the optimal medications for treating insomnia based on the "best-available evidence," but there are caveats.
- [Older Adults: Worsening Depression Can Precede Stroke](https://medworksmedia.com/older-adults-worsening-depression-can-precede-stroke/): Whereas symptoms of depression are known to intensify in patients who have recently experienced an incident stroke, it might also be true in such cases that the depression actually starts to worsen in the months or years before the stroke occurs, suggests a new study of adults 50 years and older.
- [A Miss for Novel Autism Drug](https://medworksmedia.com/a-miss-for-novel-autism-drug/): Balovaptan, a novel drug that binds to and blocks vasopressin 1A (V1a) receptors, does not improve social communication in children and adolescents with autism spectrum disorder (ASD), new research shows.
- [Roche scraps 5 trials: Alzheimer’s ‘High Risk’](https://medworksmedia.com/roche-scraps-5-trials-alzheimers-high-risk/): In a continuation of bad news for investigative Alzheimer's drugs, Roche has halted five early and midstage trials covering a range of therapeutic categories, including Alzheimer's drugs. The Swiss pharma admits that two of its most exciting prospects remain high-risk.
- [Sage, Biogen show good results on zuranolone phase 3 depression trial](https://medworksmedia.com/sage-biogen-show-good-results-on-phase-3-depression-trial/): Sage and Biogen’s depression drug quickly relieved symptoms of depression in a phase 3 trial, but the readout did little to quell concerns about the med’s durability of effect, an issue that investors and analysts have been concerned about, according to a blog published today on Fierce Biotech.
- [Bipolar spectrum disorder masquerading as treatment resistant unipolar depression](https://medworksmedia.com/bipolar-spectrum-disorder-masquerading-as-treatment-resistant-unipolar-depression/): We are frequently consulted by patients with treatment resistant depression (TRD).Reference Fogelson and Leuchter1 Many of these patients have never met criteria for a manic episode so they are not diagnosed with bipolar disorder (BPD). Consequently, they have undergone trials of antidepressants with or without augmentation therapies without success.Reference Perlis, Uher and Ostacher2 Antidepressants have caused increased agitation and anxietyReference Perlis, Smoller, Fava, Rosenbaum, Nierenberg and Sachs3, Reference Perugi, Pacchiarotti and Mainardi4 or have been ineffective. We believe that many of these patients would receive effective treatment if they were reconceptualized to be suffering from bipolar spectrum disorder (BPSD) and treated for bipolar depression. The diagnosis of major depressive disorder (MDD) with mixed featuresReference Koukopoulos and Sani5, Reference Suppes and Ostacher6 is not the same as a diagnosis of BPSD and will lead to too few patients reconceptualized as suffering from BPSD. We shall review the history and clinical characteristics of a patient with BPSD, only one of which (see Figure 1, item 8) refers to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) criteria for a mixed state.
- [Dementia-related psychosis and the potential role for pimavanserin](https://medworksmedia.com/dementia-related-psychosis-and-the-potential-role-for-pimavanserin/): No pharmacological agents are approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis (DRP). Pimavanserin, an atypical antipsychotic that acts as a selective serotonin inverse agonist/antagonist at 5-HT2A receptors (and to a lesser extent, at 5-HT2c receptors), is the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease (PD) psychosis.1, Reference Cummings, Isaacson and Mills2 A phase 2 study of pimavanserin in Alzheimer’s disease (AD) psychosis met its primary end point at week 6 (mean change in the Neuropsychiatric Inventory-Nursing Home version psychosis score of −3.76 points for pimavanserin and −1.93 points for placebo; P =0 .045) with an acceptable tolerability profile and no worsening of cognition or motor function.Reference Ballard, Banister and Khan3 Pimavanserin is being investigated (NCT03325556 and 2017-002227-13) for treating hallucinations and delusions associated with DRP across five common neurodegenerative dementias: AD dementia, PD dementia, dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and vascular dementia (VaD).4-6 This article discusses the emerging understanding of the neurobiology of psychosis, the current state of knowledge about the neurobiology of psychotic symptoms in dementia syndromes, and the hypothesized role of pimavanserin in treating DRP.
- [C.D.C. Proposes New Guidelines for Opioid Use](https://medworksmedia.com/c-d-c-proposes-new-guidelines-for-opioid-use/): The federal government on Thursday proposed new guidelines for prescribing opioid painkillers that remove its previous recommended ceilings on doses for chronic pain patients and instead encourage doctors to use their best judgment. The new guidelines were reported in today's New York Times
- [Selective publication of antidepressant trials and its influence on apparent efficacy: A meta-analyses ](https://medworksmedia.com/selective-publication-of-antidepressant-trials-and-its-influence-on-apparent-efficacy-a-meta-analyses/): Valid assessment of drug efficacy and safety requires an evidence base free of reporting bias. Using trial reports in Food and Drug Administration (FDA) drug approval packages as a gold standard,  researchers, Turner, Cipriani, Furukawa, et al. previously found that the published literature inflated the apparent efficacy of antidepressant drugs. The objective of the current study was to determine whether this has improved with recently approved drugs.
- [Psychiatric comorbidity and risk of premature mortality is significant](https://medworksmedia.com/psychiatric-comorbidity-and-risk-of-premature-mortality-is-significant/): A group of researchers aimed to determine the risks of premature mortality and suicide in people with common noncommunicable diseases, with and without psychiatric disorder comorbidity.
- [IN PRESS: 52/1/2022](https://medworksmedia.com/in-press-52-1-2022/): ORIGINAL RESEARCH
- [Orally Dissolving Buprenorphine Tied to Severe Tooth Decay](https://medworksmedia.com/orally-dissolving-buprenorphine-tied-to-severe-tooth-decay/): Orally dissolving medications containing buprenorphine are linked to severe dental problems, including total tooth loss, the US Food and Drug Administration (FDA) warns in a safety communication.

## Pages
- [For Librarians](https://medworksmedia.com/for-librarians/)
- [Librarian Portal](https://medworksmedia.com/librarian-portal/)
- [Subscriptions](https://medworksmedia.com/psychopharmacology-bulletin/subscriptions/)
- [Depression](https://medworksmedia.com/resources/psychopharmacology-101/depression/)
- [Cookie Policy](https://medworksmedia.com/cookie-policy/)
- [Terms & Conditions](https://medworksmedia.com/terms-conditions/): Last Updated: 09/24/2025
- [Licensable Psychiatric Rating Scales](https://medworksmedia.com/rating-scales/)
- [General Clinical Assessment Tools](https://medworksmedia.com/resources/assessment-tools/general-clinical-assessment-tools/)
- [Functional Assessment Tools](https://medworksmedia.com/resources/assessment-tools/functional-assessment-tools/)
- [Depression Assessment Tools](https://medworksmedia.com/resources/assessment-tools/depression-assessment-tools/)
- [Clinical Reference Guides](https://medworksmedia.com/resources/assessment-tools/clinical-reference-guides/)
- [ADHD Assessment Tools](https://medworksmedia.com/resources/assessment-tools/adhd-assessment-tools/)
- [Assessment Tools](https://medworksmedia.com/resources/assessment-tools/)
- [Issues](https://medworksmedia.com/psychopharmacology-bulletin/issues/)
- [Archive](https://medworksmedia.com/archive/)
- [The Black Book of Psychotropic Dosing & Monitoring](https://medworksmedia.com/the-black-book-of-psychotropic-dosing-monitoring/)
- [My Account](https://medworksmedia.com/my-account/): A link to set a new password will be sent to your email address.
- [Checkout](https://medworksmedia.com/checkout/)
- [Cart](https://medworksmedia.com/cart/):   You may be interested in…                       Your cart is currently empty!
- [Privacy Policy](https://medworksmedia.com/privacy-policy/): Privacy Policy Last Updated On 24-Sep-2025 Effective Date 24-Sep-2025 This Privacy Policy describes the policies of MedWorks Media Inc., 58427 Joshua Lane, California 92284, United States of America (the), email: support@medworksmedia.com, phone: (917)692-8000‬ on the collection, use and disclosure of your information that we collect when you use our website ( https://medworksmedia.com ). (the “Service”). By accessing or using the Service, you are consenting to the collection, use and disclosure of your information in accordance with this Privacy Policy. If you do not consent to the same, please do not access or use the Service. We may modify this Privacy Policy at any time without any prior notice to you and will post the revised Privacy Policy on the Service. The revised Policy will be effective 180 days from when the revised Policy is posted in the Service and your continued access or use of the Service after such time will constitute your acceptance of the revised Privacy Policy. We therefore recommend that you periodically review this page. Information We Collect: We will collect and process the following personal information about you: Name Email Payment Info How We Collect Your Information: We collect/receive information about you in the following manner: When a user fills up the registration form or otherwise submits personal information Interacts with the website From public sources How We Use Your Information: We will use the information that we collect about you for the following purposes: Marketing/ Promotional Creating user account Customer feedback collection Processing payment Administration info Manage customer order Manage user account If we want to use your information for any other purpose, we will ask you for consent and will use your information only on receiving your consent and then, only for the purpose(s) for which grant consent unless we are required to do otherwise by law. How We Share Your Information: We will not transfer your personal information to any third party without seeking your consent, except in limited circumstances as described below: Analytics Data collection & process We require such third party’s to use the personal information we transfer to them only for the purpose for which it was transferred and not to retain it for longer than is required for fulfilling the said purpose. We may also disclose your personal information for the following: (1) to comply with applicable law, regulation, court order or other legal process; (2) to enforce your agreements with us, including this Privacy Policy; or (3) to respond to claims that your use of the Service violates any third-party rights. If the Service or our company is merged or acquired with another company, your information will be one of the assets that is transferred to the new owner. Retention Of Your Information: We will retain your personal information with us for 90 days to 2 years after users terminate their accounts or for as long as we need it to fulfill the purposes for which it was collected as detailed in this Privacy Policy. We may need to retain certain information for longer periods such as record-keeping / reporting in accordance with applicable law or for other legitimate reasons like enforcement of legal rights, fraud prevention, etc. Residual anonymous information and aggregate information, neither of which identifies you (directly or indirectly), may be stored indefinitely. Your Rights: Depending on the law that applies, you may have a right to access and rectify or erase your personal data or receive a copy of your personal data, restrict or object to the active processing of your data, ask us to share (port) your personal information to another entity, withdraw any consent you provided to us to process your data, a right to lodge a complaint with a statutory authority and such other rights as may be relevant under applicable laws. To exercise these rights, you can write to us at support@medworksmedia.com. We will respond to your request in accordance with applicable law. You may opt-out of direct marketing communications or the profiling we carry out for marketing purposes by writing to us at support@medworksmedia.com. Do note that if you do not allow us to collect or process the required personal information or withdraw the consent to process the same for the required purposes, you may not be able to access or use the services for which your information was sought. Cookies Etc. To learn more about how we use these and your choices in relation to these tracking technologies, please refer to our Cookie Policy. Security: The security of your information is important to us and we will use reasonable security measures to prevent the loss, misuse or unauthorized alteration of your information under our control. However, given the inherent risks, we cannot guarantee absolute security and consequently, we cannot ensure or warrant the security of any information you transmit to us and you do so at your own risk. Grievance / Data Protection Officer: If you have any queries or concerns about the processing of your information that is available with us, you may email our Grievance Officer at MedWorks Media Inc., 58427 Joshua Lane, email: support@medworksmedia.com. We will address your concerns in accordance with applicable law. Privacy Policy generated with CookieYes.
- [Myrna M. Weissman, PhD](https://medworksmedia.com/authors-and-editorial-advisors/myrna-weissman-phd/): Dr. Myrna M. Weissman is a distinguished member of the Editorial Advisory Board of Psychopharmacology Bulletin and serves as the Diane Goldman Kemper Family Professor of Epidemiology in Psychiatry at the Vagelos College of Physicians and Surgeons and the Mailman School of Public Health at Columbia University. She is also Chief of the Division of Translational Epidemiology at New York State Psychiatric Institute.
- [K. Ranga Rama Krishnan, MB, ChB](https://medworksmedia.com/authors-and-editorial-advisors/k-ranga-rama-krishnan-mb-chb/): Dr. K. Ranga Rama Krishnan is a distinguished member of the Editorial Advisory Board of Psychopharmacology Bulletin and currently serves as Executive Vice Chairman and Senior Advisor of Rush University System for Health in Chicago. His distinguished international career spans academic medicine, healthcare administration, and groundbreaking research in psychiatry and neuroscience.
- [Philip T. Ninan, MD](https://medworksmedia.com/authors-and-editorial-advisors/philip-t-ninan-md/): Dr. Philip T. Ninan is a distinguished member of the Editorial Advisory Board of Psychopharmacology Bulletin and currently serves as Co-Founder and Chief Executive Officer of eMind Science Corp, where he has developed eMindLog™, a neuroscience-based measure for personal self-assessment and tracking of stress, anxiety, and depression. He also serves as Adjunct Professor of Psychiatry and Behavioral Sciences at Emory University School of Medicine.
- [Jack M. Gorman, MD](https://medworksmedia.com/authors-and-editorial-advisors/jack-m-gorman-md/): Dr. Jack M. Gorman is a distinguished member of the Editorial Advisory Board of Psychopharmacology Bulletin and serves as CEO and Chief Scientific Officer of Franklin Behavioral Health Consultants, where he provides expert guidance to healthcare organizations to improve the efficacy and cost-effectiveness of mental health care. He is also President and Co-founder of Critica, a non-profit organization dedicated to counteracting scientific misinformation and improving public understanding of science. He previously served as Editor-in-Chief of CNS Spectrums during MedWorks Media's ownership of the publication.
- [Steven E. Hyman, MD](https://medworksmedia.com/authors-and-editorial-advisors/steven-e-hyman-md/): Dr. Steven E. Hyman is a distinguished member of the Editorial Advisory Board of Psychopharmacology Bulletin and serves as a Core Institute Member and Director of the Program in Brain Health at the Broad Institute of MIT and Harvard. He is also Harvard University Distinguished Service Professor and Harald McPike Professor of Stem Cell and Regenerative Biology.
- [Jeffrey A. Lieberman, MD](https://medworksmedia.com/authors-and-editorial-advisors/jeffrey-a-lieberman-md/): Dr. Jeffrey A. Lieberman is a distinguished member of the Editorial Advisory Board of Psychopharmacology Bulletin and a leading authority on schizophrenia research, psychopharmacology, and clinical psychiatry. He serves as the Constance and Stephen Lieber Professor of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons, Director of the New York State Psychiatric Institute, and Psychiatrist-in-Chief at Columbia University Medical Center of the NewYork-Presbyterian Hospital.
- [Alan F. Schatzberg, MD](https://medworksmedia.com/authors-and-editorial-advisors/alan-f-schatzberg-md/): Dr. Alan F. Schatzberg is a distinguished member of the Editorial Advisory Board of Psychopharmacology Bulletin and one of the world's leading authorities in the biology and psychopharmacology of depressive disorders. His groundbreaking research has shaped our understanding of mood disorders and transformed clinical practice in psychiatry.
- [Michael E. Thase, MD](https://medworksmedia.com/authors-and-editorial-advisors/michael-e-thase-md/): Dr. Michael E. Thase serves as Editor-in-Chief of Psychopharmacology Bulletin and is a leading authority in mood disorders research and treatment. With over 40 years of clinical and research experience, Dr. Thase has dedicated his career to advancing the understanding and treatment of depression and bipolar affective disorder.
- [Charles B. Nemeroff, MD, PhD](https://medworksmedia.com/authors-and-editorial-advisors/charles-b-nemeroff-md-phd/): Dr. Charles B. Nemeroff serves as Editor Emeritus of Psychopharmacology Bulletin, having established the journal's modern reputation for excellence as founding Editor-in-Chief following MedWorks Media's acquisition from the National Institute of Mental Health in 1999. His visionary leadership transformed the publication into one of psychiatry's most respected peer-reviewed journals.
- [Authors and Editorial Advisors](https://medworksmedia.com/authors-and-editorial-advisors/): This distinguished network ensures that Psychopharmacology Bulletin and our educational resources maintain the highest standards of scientific rigor while bridging cutting-edge research with clinical practice.
- [James M. La Rossa Jr.](https://medworksmedia.com/authors-and-editorial-advisors/james-m-la-rossa-jr/): James M. La Rossa Jr. serves as Publisher and Editorial Director of Psychopharmacology Bulletin and is the visionary founder of MedWorks Media Inc. Since establishing the company in 1994, he has built the premier digital and print publishing platform for psychiatric medicine, creating publications that reach more psychiatrists, psychopharmacologists, and medical professionals than any other publisher in the field.
- [MedWorks Reprint Series](https://medworksmedia.com/archive/medworks-reprint-series/)
- [Resources](https://medworksmedia.com/resources/)
- [Psychopharmacology 101](https://medworksmedia.com/resources/psychopharmacology-101/)
- [Pocket Reference Guides](https://medworksmedia.com/archive/pocket-reference-guides/)
- [Evidence-Based Medicine](https://medworksmedia.com/resources/psychopharmacology-101/evidence-based-medicine/)
- [Cannabis](https://medworksmedia.com/resources/psychopharmacology-101/cannabis/)
- [Social Anxiety Disorder](https://medworksmedia.com/resources/psychopharmacology-101/social-anxiety-disorder/)
- [Substance Abuse](https://medworksmedia.com/resources/psychopharmacology-101/substance-abuse/)
- [Antidepressants](https://medworksmedia.com/resources/psychopharmacology-101/antidepressants/)
- [Dementia](https://medworksmedia.com/resources/psychopharmacology-101/dementia/)
- [Insomnia](https://medworksmedia.com/resources/psychopharmacology-101/insomnia/)
- [Peer Review and Index Medicus](https://medworksmedia.com/resources/psychopharmacology-101/peer-review-index-medicus/)
- [Psychopharmacology](https://medworksmedia.com/resources/psychopharmacology-101/psychopharmacology/)
- [Alzheimer’s Disease](https://medworksmedia.com/resources/psychopharmacology-101/alzheimers-disease/)
- [ADHD](https://medworksmedia.com/resources/psychopharmacology-101/adhd/)
- [Generalized Anxiety Disorder (GAD)](https://medworksmedia.com/resources/psychopharmacology-101/generalized-anxiety-disorder-gad/)
- [Anxiety Disorders](https://medworksmedia.com/resources/psychopharmacology-101/anxiety-disorders/)
- [Benzodiazepines](https://medworksmedia.com/resources/psychopharmacology-101/benzodiazepines/)
- [Anxiety Medications](https://medworksmedia.com/resources/psychopharmacology-101/anxiety-medications/)

## Articles
- [When Care Becomes Dangerous: Patient Assaults Against Physicians](https://medworksmedia.com/pb-article/when-care-becomes-dangerous-patient-assaults-against-physicians/)
- [Psychopharmacology of Eugeroics—The Whole Nine Yards!](https://medworksmedia.com/pb-article/psychopharmacology-of-eugeroics-the-whole-nine-yards/)
- [Escitalopram-Induced Spasmodic Torticollis in an Early Psychosis Service: A Case Report](https://medworksmedia.com/pb-article/escitalopram-induced-spasmodic-torticollis-in-an-early-psychosis-service-a-case-report/)
- [Cariprazine for Autism—A Case Report](https://medworksmedia.com/pb-article/cariprazine-for-autism-a-case-report/)
- [Mirtazapine-Induced Asymptomatic Hepatotoxicity: A Case Report](https://medworksmedia.com/pb-article/mirtazapine-induced-asymptomatic-hepatotoxicity-a-case-report/)
- [Breaking the Cycle of Insomnia and Depression: Agomelatine in Adolescent Bipolar Disorder](https://medworksmedia.com/pb-article/breaking-the-cycle-of-insomnia-and-depression-agomelatine-in-adolescent-bipolar-disorder/)
- [Can Abrupt Discontinuation of Clozapine Cause Seizures?](https://medworksmedia.com/pb-article/can-abrupt-discontinuation-of-clozapine-cause-seizures/)
- [Electroconvulsive Therapy and Ketamine Infusion in Patients with Bipolar I or II Depression: A Case Series](https://medworksmedia.com/pb-article/electroconvulsive-therapy-and-ketamine-infusion-in-patients-with-bipolar-i-or-ii-depression-a-case-series/)
- [Beyond Clozapine: Myocarditis and Cardiomyopathy Associated with Antipsychotic Medications—An Updated Narrative Review for Psychiatric Practice](https://medworksmedia.com/pb-article/beyond-clozapine-myocarditis-and-cardiomyopathy-associated-with-antipsychotic-medications-an-updated-narrative-review-for-psychiatric-practice/)
- [Traumatic Brain Injury and Delusional Disorder: A Narrative Synthesis with Psychopharmacologic Implications](https://medworksmedia.com/pb-article/traumatic-brain-injury-and-delusional-disorder-a-narrative-synthesis-with-psychopharmacologic-implications/)
- [Beyond Exposure: Standardizing Buprenorphine Training in Pain Medicine Fellowship](https://medworksmedia.com/pb-article/beyond-exposure-standardizing-buprenorphine-training-in-pain-medicine-fellowship/)
- [Evidence-Based Pharmacotherapies for Major Depressive Disorder: A Clinical Update](https://medworksmedia.com/pb-article/evidence-based-pharmacotherapies-for-major-depressive-disorder-a-clinical-update/)
- [Efficacy and Safety of Deutetrabenazine in Tourette Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials](https://medworksmedia.com/pb-article/efficacy-and-safety-of-deutetrabenazine-in-tourette-syndrome-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/)
- [Efficacy and Safety of Centanafadine in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials](https://medworksmedia.com/pb-article/efficacy-and-safety-of-centanafadine-in-attention-deficit-hyperactivity-disorder-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/)
- [Catatonia Associated with Psychosis: A Retrospective Study of 164 Inpatients](https://medworksmedia.com/pb-article/catatonia-associated-with-psychosis-a-retrospective-study-of-164-inpatients/)
- [Association of CBC-Derived Indices of Inflammation with Response to Glecaprevir/Pibrentasvir for PTSD](https://medworksmedia.com/pb-article/association-of-cbc-derived-indices-of-inflammation-with-response-to-glecaprevir-pibrentasvir-for-ptsd/)
- [GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial](https://medworksmedia.com/pb-article/gh001-efficacy-is-independent-of-prior-antidepressant-treatment-failures-in-treatment-resistant-depression-a-post-hoc-analysis-of-a-phase-2b-randomized-controlled-trial/)
- [Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials](https://medworksmedia.com/pb-article/efficacy-and-safety-of-asenapine-in-bipolar-disorder-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/)
- [Academic Stress in Dental Students Analysis: Questionnaire Design and Validation Study](https://medworksmedia.com/pb-article/academic-stress-in-dental-students-analysis-questionnaire-design-and-validation-study/)
- [Suzetrigine for Pain Management: An Observational Study of Early Adoption Patterns](https://medworksmedia.com/pb-article/suzetrigine-for-pain-management-an-observational-study-of-early-adoption-patterns/)
- [Smoking Status Among Patients Presenting to a Chronic Pain Clinic: A Retrospective Review from a University-Affiliated Pain Clinic](https://medworksmedia.com/pb-article/smoking-status-among-patients-presenting-to-a-chronic-pain-clinic-a-retrospective-review-from-a-university-affiliated-pain-clinic/)
- [A Retrospective Study of Mood and Anxiety Disorders Management Profile (MooD-MaP) of Patients Admitted at the Makati Medical Center from 2014–2017](https://medworksmedia.com/pb-article/a-retrospective-study-of-mood-and-anxiety-disorders-management-profile-mood-map-of-patients-admitted-at-the-makati-medical-center-from-2014-2017/)
- [Clavulanic Acid Attenuated Cocaine Craving in Individuals with Cocaine Use Disorder](https://medworksmedia.com/pb-article/clavulanic-acid-attenuated-cocaine-craving-in-individuals-with-cocaine-use-disorder/)
- [Body Dysmorphic Disorder Among Young Individuals: Prevalence and Psychological Correlates](https://medworksmedia.com/pb-article/body-dysmorphic-disorder-among-young-individuals-prevalence-and-psychological-correlates/)
- [Incidence and Risk Factors of Clozapine-Induced Neutropenia among Patients with Schizophrenia in Taif, Saudi Arabia](https://medworksmedia.com/pb-article/incidence-and-risk-factors-of-clozapine-induced-neutropenia-among-patients-with-schizophrenia-in-taif-saudi-arabia/)
- [Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis](https://medworksmedia.com/pb-article/comparative-effectiveness-of-naltrexone-formulations-in-alcohol-use-disorder-an-updated-meta-analysis/)
- [Antipsychotics—Therapeutic Salve or Iatrogenic Thorn?](https://medworksmedia.com/pb-article/antipsychotics-therapeutic-salve-or-iatrogenic-thorn/)
- [Current Concepts and Treatment Options in the Management of Fibromyalgia](https://medworksmedia.com/pb-article/current-concepts-and-treatment-options-in-the-management-of-fibromyalgia/)
- [Case Series: Simultaneous Use of Long-Acting Injectable Antipsychotics and Vivitrol or Long-Acting Buprenorphine in Dual Diagnosis Patients with Bipolar Disorder and Substance Use Disorders](https://medworksmedia.com/pb-article/case-series-simultaneous-use-of-long-acting-injectable-antipsychotics-and-vivitrol-or-long-acting-buprenorphine-in-dual-diagnosis-patients-with-bipolar-disorder-and-substance-use-disorders/)
- [Psychopharmacotherapy of Alzheimer’s Disease—What Do We Have at Hand?](https://medworksmedia.com/pb-article/psychopharmacotherapy-of-alzheimers-disease-what-do-we-have-at-hand/)
- [Agomelatine-Induced Subjective Double Delusion in Adolescent Bipolar Disorder](https://medworksmedia.com/pb-article/agomelatine-induced-subjective-double-delusion-in-adolescent-bipolar-disorder/)
- [Missing the Forest for the Trees: Delayed Diagnosis and Management of Treatment Resistant Schizophrenia](https://medworksmedia.com/pb-article/missing-the-forest-for-the-trees-delayed-diagnosis-and-management-of-treatment-resistant-schizophrenia/)
- [Case Report: Valproate Induced Hyperammonaemic Encephalopathy in a Psychiatric Inpatient](https://medworksmedia.com/pb-article/case-report-valproate-induced-hyperammonaemic-encephalopathy-in-a-psychiatric-inpatient/)
- [The Management of Evolving Neuropsychiatric Symptoms in a Female with Fragile X Syndrome: A Case Report](https://medworksmedia.com/pb-article/the-management-of-evolving-neuropsychiatric-symptoms-in-a-female-with-fragile-x-syndrome-a-case-report/)
- [Non-Catatonic Mutism as a Presentation of Psychosis: A Case Study](https://medworksmedia.com/pb-article/non-catatonic-mutism-as-a-presentation-of-psychosis-a-case-study/)
- [A Journey Through Suicidality: Recurrent Attempts, Method Switching, and Psychiatric Diagnostic Challenges](https://medworksmedia.com/pb-article/a-journey-through-suicidality-recurrent-attempts-method-switching-and-psychiatric-diagnostic-challenges/)
- [The Use of Lorazepam for Acute Episodes in a Patient with Kleine-Levin Syndrome: A Longitudinal Case Report](https://medworksmedia.com/pb-article/the-use-of-lorazepam-for-acute-episodes-in-a-patient-with-kleine-levin-syndrome-a-longitudinal-case-report/)
- [The Intersection of Gender Dysphoria (GD) and Autism Spectrum Disorder (ASD): A Case Series](https://medworksmedia.com/pb-article/the-intersection-of-gender-dysphoria-gd-and-autism-spectrum-disorder-asd-a-case-series/)
- [The Intersections of Fetal Alcohol Syndrome with Autism Spectrum Disorder and Mood Dysregulation: A Rare Case of Behavioral Complexity](https://medworksmedia.com/pb-article/the-intersections-of-fetal-alcohol-syndrome-with-autism-spectrum-disorder-and-mood-dysregulation-a-rare-case-of-behavioral-complexity/)
- [Multisystem Sequelae of Chronic Diphenhydramine Misuse in an Adolescent: A Case Highlighting the Importance of Comprehensive History-Taking](https://medworksmedia.com/pb-article/multisystem-sequelae-of-chronic-diphenhydramine-misuse-in-an-adolescent-a-case-highlighting-the-importance-of-comprehensive-history-taking/)
- [Lamotrigine-Induced DRESS Syndrome with Myelosuppression in a Patient with Bipolar Disorder: Case Report](https://medworksmedia.com/pb-article/lamotrigine-induced-dress-syndrome-with-myelosuppression-in-a-patient-with-bipolar-disorder-case-report/)
- [Emerging Innovations in Third- and Fourth-Generation Antipsychotics: Mechanistic Advances and Clinical Implications](https://medworksmedia.com/pb-article/emerging-innovations-in-third-and-fourth-generation-antipsychotics-mechanistic-advances-and-clinical-implications/)
- [Lorazepam-Assisted Interview in Clinical Psychiatry: A Narrative Review of Current Evidence and Research Gaps](https://medworksmedia.com/pb-article/lorazepam-assisted-interview-in-clinical-psychiatry-a-narrative-review-of-current-evidence-and-research-gaps/)
- [A Pilot Study Exploring the Impact of Pro Re Nata Medication Utilization on Aggression in Forensic Psychiatric Patients](https://medworksmedia.com/pb-article/a-pilot-study-exploring-the-impact-of-pro-re-nata-medication-utilization-on-aggression-in-forensic-psychiatric-patients/)
- [Personalizing Treatment for Acute Alcoholic Hallucinosis: Clinical Utility of Integrated Pharmacogenetic Testing, Metabolic Phenotyping, and microRNA Biomarkers](https://medworksmedia.com/pb-article/personalizing-treatment-for-acute-alcoholic-hallucinosis-clinical-utility-of-integrated-pharmacogenetic-testing-metabolic-phenotyping-and-microrna-biomarkers/)
- [Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool](https://medworksmedia.com/pb-article/risk-of-obesity-in-patients-treated-with-clozapine-or-olanzapine-a-simple-clinically-useful-prediction-tool/)
- [Tramadol Utilization Patterns: A One-Year Retrospective Review](https://medworksmedia.com/pb-article/tramadol-utilization-patterns-a-one-year-retrospective-review/)
- [Glecaprevir/Pibrentasvir for Post Traumatic Stress Disorder](https://medworksmedia.com/pb-article/glecaprevir-pibrentasvir-for-post-traumatic-stress-disorder/)
- [Trends in Opioid Prescribing and Co-Prescription of Opioid Antagonists: A Retrospective Analysis over a 12-Month Period](https://medworksmedia.com/pb-article/trends-in-opioid-prescribing-and-co-prescription-of-opioid-antagonists-a-retrospective-analysis-over-a-12-month-period/)
- [Differences in the Prevalence of Use and Dosage of Psychotropic Drugs by Smoking Status in Inpatient and Outpatient: An Observational, Analytical, Cross-Sectional Study](https://medworksmedia.com/pb-article/differences-in-the-prevalence-of-use-and-dosage-of-psychotropic-drugs-by-smoking-status-in-inpatient-and-outpatient-an-observational-analytical-cross-sectional-study/)

## Psychotropic
- [Varenicline | Chantix](https://medworksmedia.com/resources/psychotropics-a-z/varenicline-chantix/): Amoxapine | Asendin
- [Sodium Oxybate | Xyrem](https://medworksmedia.com/resources/psychotropics-a-z/sodium-oxybate-xyrem/): Amoxapine | Asendin
- [Sertraline | Zoloft](https://medworksmedia.com/resources/psychotropics-a-z/sertraline-zoloft/): Amoxapine | Asendin
- [Sertindole | Serdolect](https://medworksmedia.com/resources/psychotropics-a-z/sertindole-serdolect/): Amoxapine | Asendin
- [Selegiline | Eldepryl](https://medworksmedia.com/resources/psychotropics-a-z/selegiline-eldepryl/): Amoxapine | Asendin
- [Rivastigmine | Exelon](https://medworksmedia.com/resources/psychotropics-a-z/rivastigmine-exelon/): Amoxapine | Asendin
- [Risperidone | Risperdal](https://medworksmedia.com/resources/psychotropics-a-z/risperidone-risperdal/): Amoxapine | Asendin
- [Reboxetine | Norebox](https://medworksmedia.com/resources/psychotropics-a-z/reboxetine-norebox/): Amoxapine | Asendin
- [Ramelteon | Rozerem](https://medworksmedia.com/resources/psychotropics-a-z/ramelteon-rozerem/): Amoxapine | Asendin
- [Quetiapine | Seroquel](https://medworksmedia.com/resources/psychotropics-a-z/quetiapine-seroquel/): Amoxapine | Asendin
- [Quazepam | Dora](https://medworksmedia.com/resources/psychotropics-a-z/quazepam-dora/)
- [Protriptyline | Triptil](https://medworksmedia.com/resources/psychotropics-a-z/protriptyline-triptil/): Amoxapine | Asendin
- [Propranolol | Inderal](https://medworksmedia.com/resources/psychotropics-a-z/propranolol-inderal/): Amoxapine | Asendin
- [Procyclidine | Kemadrin](https://medworksmedia.com/resources/psychotropics-a-z/procyclidine-kemadrin/): Amoxapine | Asendin
- [Suvorexant | Belsomra](https://medworksmedia.com/resources/psychotropics-a-z/suvorexant-belsomra/)
- [Sulpiride | Dolmatil](https://medworksmedia.com/resources/psychotropics-a-z/sulpiride-dolmatil/): Amoxapine | Asendin
- [Venlafaxine | Effexor](https://medworksmedia.com/resources/psychotropics-a-z/venlafaxine-effexor/): Amoxapine | Asendin
- [Temazepam | Restoril](https://medworksmedia.com/resources/psychotropics-a-z/temazepam-restoril/): Amoxapine | Asendin
- [Valproic Acid/750–4,200 | Depakene](https://medworksmedia.com/resources/psychotropics-a-z/valproic-acid-750-4200-depakene/): Amoxapine | Asendin
- [Trimipramine Maleate | Surmontil](https://medworksmedia.com/resources/psychotropics-a-z/trimipramine-maleate-surmontil/): Amoxapine | Asendin
- [Trihexyphenidyl | Artane](https://medworksmedia.com/resources/psychotropics-a-z/trihexyphenidyl-artane/): Amoxapine | Asendin
- [Triazolam | Halcion](https://medworksmedia.com/resources/psychotropics-a-z/triazolam-halcion/): Amoxapine | Asendin
- [Trifluopearzine | Stelazine](https://medworksmedia.com/resources/psychotropics-a-z/trifluopearzine-stelazine/): Amoxapine | Asendin
- [Trazadone XR | Oleptro](https://medworksmedia.com/resources/psychotropics-a-z/trazadone-xr-oleptro/): Amoxapine | Asendin
- [Trazodone | Desyrel](https://medworksmedia.com/resources/psychotropics-a-z/trazodone-desyrel/): Amoxapine | Asendin
- [Tranylcypromine | Parnate](https://medworksmedia.com/resources/psychotropics-a-z/tranylcypromine-parnate/): Amoxapine | Asendin
- [Topiramate | Topamax](https://medworksmedia.com/resources/psychotropics-a-z/topiramate-topamax/): Amoxapine | Asendin
- [Tianeptine | Coaxil](https://medworksmedia.com/resources/psychotropics-a-z/tianeptine-coaxil/): Amoxapine | Asendin
- [Thiothixene | Navane](https://medworksmedia.com/resources/psychotropics-a-z/thiothixene-navane/): Amoxapine | Asendin
- [Thioridazine | Mellaril](https://medworksmedia.com/resources/psychotropics-a-z/thioridazine-mellaril/): Amoxapine | Asendin
- [Pregabalin | Lyrica](https://medworksmedia.com/resources/psychotropics-a-z/pregabalin-lyrica/)
- [Pimozide | Orap](https://medworksmedia.com/resources/psychotropics-a-z/pimozide-orap/): Amoxapine | Asendin
- [Milnacipran | Savella](https://medworksmedia.com/resources/psychotropics-a-z/milnacipran-savella/): Amoxapine | Asendin
- [Mianserin | Lerivon](https://medworksmedia.com/resources/psychotropics-a-z/mianserin-lerivon/): Amoxapine | Asendin
- [Hydroxyzine | Atarax](https://medworksmedia.com/resources/psychotropics-a-z/hydroxyzine-atarax/): Amoxapine | Asendin
- [Haloperidol | Haldol](https://medworksmedia.com/resources/psychotropics-a-z/haloperidol-haldol/): Haloperidol | Haldol
- [Flurazepam | Dalmane](https://medworksmedia.com/resources/psychotropics-a-z/flurazepam-dalmane/): Amoxapine | Asendin
- [Flupenthixol | Depixol](https://medworksmedia.com/resources/psychotropics-a-z/flupenthixol-depixol/): Amoxapine | Asendin
- [Estazolam | ProSom](https://medworksmedia.com/resources/psychotropics-a-z/estazolam-prosom/): Amoxapine | Asendin
- [Dextromethorphan | Nuedexta](https://medworksmedia.com/resources/psychotropics-a-z/dextromethorphan-nuedexta/): Dextromethorphan | Nuedexta
- [Diphenhydramine | Benadryl](https://medworksmedia.com/resources/psychotropics-a-z/diphenhydramine-benadryl/): Amoxapine | Asendin
- [Disulfiram | Antabuse](https://medworksmedia.com/resources/psychotropics-a-z/disulfiram-antabuse/): Amoxapine | Asendin
- [Droperidol | Inapsine](https://medworksmedia.com/resources/psychotropics-a-z/droperidol-inapsine/): Amoxapine | Asendin
- [Blonanserin | Lonasen](https://medworksmedia.com/resources/psychotropics-a-z/blonanserin-lonasen/): Amoxapine | Asendin
- [Mirtazapine | Remeron](https://medworksmedia.com/resources/psychotropics-a-z/mirtazapine-remeron/): Amoxapine | Asendin
- [Biperiden | Akineton](https://medworksmedia.com/resources/psychotropics-a-z/biperiden-akineton/): Amoxapine | Asendin
- [Molindone | Moban](https://medworksmedia.com/resources/psychotropics-a-z/molindone-moban/): Amoxapine | Asendin
- [Modafinil | Provigil](https://medworksmedia.com/resources/psychotropics-a-z/modafinil-provigil/): Amoxapine | Asendin
- [Pimavanserin | Nuplazid](https://medworksmedia.com/resources/psychotropics-a-z/pimavanserin-nuplazid/)
- [Phenelzine | Nardil](https://medworksmedia.com/resources/psychotropics-a-z/phenelzine-nardil/): Amoxapine | Asendin

## Rating Scales
- [(GDS-30)© – Geriatric Depression Scale Long Form](https://medworksmedia.com/rating-scales/geriatric-depression-scale-long-form-gds-30/)
- [(GDS-SV)© – Geriatric Depression Scale Short Version](https://medworksmedia.com/rating-scales/geriatric-depression-scale-short-version-gds-sv/)
- [(PQ-LES-Q)© – Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire](https://medworksmedia.com/rating-scales/pediatric-quality-of-life-enjoyment-and-satisfaction-questionnaire-pq-les-q/)
- [18 (Q-LES-Q-18)© – Quality of Life Enjoyment and Satisfaction Questionnaire](https://medworksmedia.com/rating-scales/quality-of-life-enjoyment-and-satisfaction-questionnaire-18-q-les-q-18/)
- [(Q-LES-Q-SF)© – Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form](https://medworksmedia.com/rating-scales/quality-of-life-enjoyment-and-satisfaction-questionnaire-short-form-q-les-q-sf/)
- [(Q-LES-Q)© – Quality of Life Enjoyment and Satisfaction Questionnaire](https://medworksmedia.com/rating-scales/quality-of-life-enjoyment-and-satisfaction-questionnaire-q-les-q/)
- [Functional Assessment Staging (FAST)](https://medworksmedia.com/rating-scales/functional-assessment-staging-fast/)
- [Brief Psychiatric Rating Scale by Psychopharmacology Bulletin (BPRS)](https://medworksmedia.com/rating-scales/brief-psychiatric-rating-scale/)
- [Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia – A Reference Guide](https://medworksmedia.com/rating-scales/rating-scales-safety-measurements-bipolar-disorder-schizophrenia-reference-guide/): Armed with this information, the healthcare professional may be better able to understand and evaluate the clinical evidence for the use of medications for the treatment of bipolar disorder and schizophrenia.
- [Wender Utah Rating Scale (WURS)](https://medworksmedia.com/rating-scales/wender-utah-rating-scale-wurs/): Wender Utah Rating Scale (WURS)
- [Vanderbilt ADHD Diagnostic Teacher Rating Scale](https://medworksmedia.com/rating-scales/vanderbilt-adhd-diagnostic-teacher-rating-scale/): Vanderbilt ADHD Diagnostic Teacher Rating Scale
- [Vanderbilt ADHD Diagnostic Parent Rating Scale](https://medworksmedia.com/rating-scales/vanderbilt-adhd-diagnostic-parent-rating-scale/): Vanderbilt ADHD Diagnostic Parent Rating Scale
- [Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist](https://medworksmedia.com/rating-scales/adult-adhd-self-report-scale-asrs-v1-1-symptom-checklist/): Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist
- [Zung Self-Rating Depression Scale](https://medworksmedia.com/rating-scales/zung-self-rating-depression-scale/): Zung Self-Rating Depression Scale
- [Major (ICD-10) Depression Inventory](https://medworksmedia.com/rating-scales/major-icd-10-depression-inventory/): Major (ICD-10) Depression Inventory
- [Patient Health Questionnaire (PHQ)](https://medworksmedia.com/rating-scales/patient-health-questionnaire/): Patient Health Questionnaire
- [Quick Inventory of Depressive Symptomatology—Self-Report (QIDS-SR)](https://medworksmedia.com/rating-scales/quick-inventory-of-depressive-symptomatology-self-report-qids-sr/): Quick Inventory of Depressive Symptomatology—Self-Report (QIDS-SR)
- [The Hamilton Rating Scale for Depression](https://medworksmedia.com/rating-scales/the-hamilton-rating-scale-for-depression/): The Hamilton Rating Scale for Depression
- [DASS21 (Depression, Anxiety & Stress Scale)](https://medworksmedia.com/rating-scales/dass21/): DASS21
- [Cornell Scale for Depression in Dementia](https://medworksmedia.com/rating-scales/cornell-scale-for-depression-in-dementia/): Cornell Scale for Depression in Dementia
- [Clinical Global Impressions (CGI)](https://medworksmedia.com/rating-scales/clinical-global-impressions-cgi/): Clinical Global Impressions (CGI)
- [Center for Epidemiologic Studies Depression Scale (CES-D)](https://medworksmedia.com/rating-scales/center-for-epidemiologic-studies-depression-scale-ces-d-nimh/): Center for Epidemiologic Studies Depression Scale (CES-D)
- [The Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Program Bipolar Depression Algorithm](https://medworksmedia.com/rating-scales/the-psychopharmacology-algorithm-project-at-the-harvard-south-shore-psychiatry-program-bipolar-depression-algorithm/): The Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Program Bipolar Depression Algorithm